|
|
|
Pharmaceutical Manufacturing and Packing Sourcer
|
Picking up on the thread of my last editorial in the Summer issue of PMPS, it's painful to hear of the widespread shake-out going on throughout our industry. It seems that no organisation is so big that it can't get bigger through consolidation, without shedding layers of management or teams of skilled professionals, while none is so small that it lacks scope for becoming even leaner by downsizing. In the current climate of economic downturn, the bottom line is that accounts matter a great deal for the survival of businesses as the struggle continues to prune costs and aim for profitability.
Browsing the bumper crop of articles in the current and recent issues of PMPS, it appears that intellectual property (IP) has moved centre stage from the periphery of the
life science arena. In one corner are illegal counterfeiting practices, out to make a fast buck from pushing pirated versions of drugs by exploiting an unfulfilled consumer-driven demand (see page 109). In another there's a rising tide of products losing their patent protection and opening the way for cheaper generic versions, meeting the need for governments to contain costs (see page88). This leaves big pharma with the enormous task of replenishing its depleted development pipeline with innovative products from the biotech sector, while remaining saddled with the mounting costs of development. Overseeing this turf war is the regulatory gamekeeper barely able to keep up with the game (see page 72 on EU Clinical Trials Directive).
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Registration Opens for Inaugural HPAPI USA Conference in October
The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.
More info >> |
|
 |
White Papers |
 |
|
Using Device Strategy to Drive R&D Productivity
Phillips-Medisize
More info >> |
|
 |
Industry Events |
 |
The Universe of Pre-filled Syringes and Injection Devices
22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel
PDA’s Universe of Pre-filled Syringes and Injection
Devices has become the must-attend meeting for everyone
working in the field, and is now the world’s largest conference on this subject
More info >> |
|
|
